ArticleInternational journal of nanomedicine2019
Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study.
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 36 citations in OpenAlex.
- Development of a Prostate-Specific Antigen Targeted Dual Drug Conjugate for Prostate Cancer Therapy.ACS omega · 2025Article
- Article
- Research Progress of SN38 Drug Delivery System in Cancer Treatment.International journal of nanomedicine · 2024Review
- Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances.International journal of molecular sciences · 2023Review
- A Review on Nanocarrier Mediated Treatment and Management of Triple Negative Breast Cancer: A Saudi Arabian Scenario.Frontiers in oncology · 2022Review
- Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients.Materials (Basel, Switzerland) · 2021Review
- BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy.Translational oncology · 2021Article
- Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.International journal of molecular sciences · 2020Review
- A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy.Journal of oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany novel drug delivery systems have been extensively studied to exploit the full therapeutic potential of SN38, which is one of the most potent antitumor analogs of camptothecins (CPTs), whose clinical application is seriously hindered by poor water solubility, low plasmatic stability, and severe toxicity, but results are always unsatisfactory.
methodsIn this study, combining the advantages of prodrug and nanotechnology, a lipophilic prodrug of SN38, SN38-PA, was developed by conjugating palmitic acid to SN38 via ester bond at C
resultsThe SN38-PA liposomes were characterized as follows: an average particle size of 80.13 nm, an average zeta potential of -33.53 mv, and the entrapment efficiency of 99%. Compared with CPT-11, SN38-PA liposome was more stable in close lactone form, more efficient in conversion rate to SN38, and more potent in cytotoxicity against tumor cells. Pharmacokinetic study showed that SN38-PA liposome had significantly enhanced plasma half-life (t
conclusionThese encouraging data merit further investigation on this novel SN38-PA liposome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.